Literature DB >> 27633444

Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles.

Yu Sakurai1, Tomoya Hada1, Shoshiro Yamamoto1, Akari Kato1, Wataru Mizumura1, Hideyoshi Harashima1.   

Abstract

A number of nano drug delivery systems have recently been developed for cancer treatment, most of which are based on the enhanced permeability and retention effect. The advantages of the enhanced permeability and retention effect can be attributed to immature vasculature. Herein we evaluated the intratumoral distribution of lipid nanoparticles when the VEGF receptor 2 on tumor endothelial cells was inhibited by liposomal siRNA. VEGF receptor 2 inhibition resulted in an increase in intratumoral distribution and therapeutic efficacy despite the maturation of the tumor vasculature. A small molecule inhibitor against matrix metalloproteinase and macrophage depletion cancelled the improvement in the distribution of the lipid nanoparticles, suggesting that remodeling of tumor microenvironment played a role in the facilitated intratumoral distribution via the down-regulation of VEGF receptor 2. Accordingly, our results suggest that the enhanced permeability and retention effect is dependent, not only on the structure of the tumor vasculature, but also on the dynamics of the tumor microenvironment including extracellular matrix remodeling. Regulating the tumor microenvironment and the extracellular matrix by delivering tumor endothelial cell-targeting siRNA could potentiate the enhanced permeability and retention effect-based strategy.

Entities:  

Year:  2016        PMID: 27633444      PMCID: PMC5167784          DOI: 10.1038/mt.2016.178

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

Review 1.  Emerging therapeutic approaches in renal cell carcinoma.

Authors:  Hiral Parekh; Brian I Rini
Journal:  Expert Rev Anticancer Ther       Date:  2015-09-17       Impact factor: 4.512

Review 2.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

3.  Tumor stromal phenotypes define VEGF sensitivity--response.

Authors:  Neil R Smith; Dawn Baker; Matthew Farren; Aurelien Pommier; Ruth Swann; Xin Wang; Sunita Mistry; Karen McDaid; Jane Kendrew; Chris Womack; Stephen R Wedge; Simon T Barry
Journal:  Clin Cancer Res       Date:  2014-10-01       Impact factor: 12.531

Review 4.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy.

Authors:  Yoshihiro Komohara; Yukio Fujiwara; Koji Ohnishi; Motohiro Takeya
Journal:  Adv Drug Deliv Rev       Date:  2015-11-24       Impact factor: 15.470

Review 5.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Authors:  Shuang Liu
Journal:  Mol Pharm       Date:  2006 Sep-Oct       Impact factor: 4.939

6.  Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts.

Authors:  Xiangpeng Zheng; Beth A Goins; Ivan L Cameron; Cristina Santoyo; Ande Bao; Victoria C Frohlich; Gary D Fullerton
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

7.  Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.

Authors:  Yu Sakurai; Hiroto Hatakeyama; Hidetaka Akita; Hideyoshi Harashima
Journal:  Mol Pharm       Date:  2014-05-12       Impact factor: 4.939

8.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

9.  Hyaluronidase To Enhance Nanoparticle-Based Photodynamic Tumor Therapy.

Authors:  Hua Gong; Yu Chao; Jian Xiang; Xiao Han; Guosheng Song; Liangzhu Feng; Jingjing Liu; Guangbao Yang; Qian Chen; Zhuang Liu
Journal:  Nano Lett       Date:  2016-03-31       Impact factor: 11.189

10.  In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.

Authors:  Tsunamasa Watanabe; Hiroto Hatakeyama; Chiho Matsuda-Yasui; Yusuke Sato; Masayuki Sudoh; Asako Takagi; Yuichi Hirata; Takahiro Ohtsuki; Masaaki Arai; Kazuaki Inoue; Hideyoshi Harashima; Michinori Kohara
Journal:  Sci Rep       Date:  2014-04-23       Impact factor: 4.379

View more
  5 in total

Review 1.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Authors:  Haifa Shen; Tong Sun; Hanh H Hoang; Jana S Burchfield; Gillian F Hamilton; Elizabeth A Mittendorf; Mauro Ferrari
Journal:  Semin Immunol       Date:  2017-09-23       Impact factor: 11.130

Review 2.  Nanomaterial-Enabled Cancer Therapy.

Authors:  Sabina Quader; Kazunori Kataoka
Journal:  Mol Ther       Date:  2017-05-19       Impact factor: 11.454

Review 3.  The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities.

Authors:  Christiana M Neophytou; Myrofora Panagi; Triantafyllos Stylianopoulos; Panagiotis Papageorgis
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

4.  Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.

Authors:  Nako Maishi; Yu Sakurai; Hiroto Hatakeyama; Yui Umeyama; Takashi Nakamura; Rikito Endo; Mohammad Towfik Alam; Cong Li; Dorcas Akuba-Muhyia Annan; Hiroshi Kikuchi; Hirofumi Morimoto; Masahiro Morimoto; Kosuke Akiyama; Noritaka Ohga; Yasuhiro Hida; Hideyoshi Harashima; Kyoko Hida
Journal:  Cancer Sci       Date:  2022-03-21       Impact factor: 6.518

Review 5.  Targeting Tumor Endothelial Cells with Nanoparticles.

Authors:  Yu Sakurai; Hidetaka Akita; Hideyoshi Harashima
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.